News for Solid Biosciences Inc. (SLDB)

Key Takeaways: Solid Biosciences (SLDB) receives Fast Track designation from the U.S. FDA for its gene therapy, SGT-501. Analysts' average target price o

Solid Biosciences (SLDB) received FDA Fast Track designation for SGT-501, a gene therapy for CPVT. SGT-501 aims to deliver the functional CASQ2 gene, ta

PR NewswirePHILADELPHIA, July 10, 2025 PHILADELPHIA, July 10, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating Solid

Solid Biosciences secures FDA and Health Canada approval for SGT-501, a gene therapy aimed at heart disease. Analysts predict substantial upside potenti

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the best stocks to invest in for a quick return. Citi initiated coverage on Solid Biosciences Inc. (NASDAQ:SLDB) with a ‘Buy’ rating, setting its price target at $14 on June 26, 2025. Citing strong potential in the Duchenne Muscular Dystrophy (DMD) market, the analyst discussed a compelling valuation […]

- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -

CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 'Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 105,330 restricted stock units ('RSUs”) to seven newly hired employees.

Solid Biosciences (SLDB) has received a fresh rating from Citigroup as the analyst Yigal Nochomovitz initiates coverage on the biotechnology company. The rating

Market Analysis by covering: Sarepta Therapeutics Inc, Solid Biosciences LLC. Read 's Market Analysis on Investing.com

Commissioner says agency is hiring scientists as industry warns over delays

Solid Biosciences (SLDB) is receiving positive attention from H.C. Wainwright, which has reaffirmed its Buy rating on the company. This decision follows a signi

U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday. Shares of Sarepta Therapeutics, Inc. SRPT fell sharpl...

Shares of Incyte Corporation INCY rose sharply in today's pre-market trading. QIAGEN and Incyte disclosed a precision medicine collaboration to develop compani...

On June 6, 2025, Solid Biosciences (SLDB) received an update from analyst Silvan Tuerkcan at JMP Securities. The analyst reiterated a Market Outperform rating f

Solid Biosciences, identified by the ticker SLDB, has allocated 34,550 restricted stock units (RSUs) to two of its recently onboarded employees. The RSUs are se

CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the

On May 22, 2025, Cantor Fitzgerald analyst Kristen Kluska announced a new price target for Solid Biosciences (SLDB), setting it at $16.00 USD. This adjustment m

Solid Biosciences (SLDB) continues to attract attention as Chardan Capital's analyst, Geulah Livshits, maintains the stock's current

**media[625381]**